Pekka Anttila

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Meletios Α. Dimopoulos, Antonio Palumbo, Paolo Corradini et al. · Blood · 2016 · 162 citations · Full text

Medicine, Hematology, Oncology +15

The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia

Riitta Jantunen, Eeva Juvonen, Esko Ikkala et al. · Annals of Hematology · 2001 · 64 citations

Medicine, Hematology, Internal Medicine +14

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen

Juho J. Miettinen, Romika Kumari, Gunnhildur Ásta Traustadóttir et al. · Cancers · 2021 · 53 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma

Raija Silvennoinen, Pekka Anttila, Marjaana Säily et al. · Bone Marrow Transplantation · 2015 · 52 citations · Full text

Medicine, Oncology, Cell Therapy +16